Patterns of care and survival among small cell lung cancer patients: Experience from a tertiary center in India  by Julka, Pramod K. et al.
Journal of the Egyptian National Cancer Institute xxx (2016) xxx–xxxContents lists available at ScienceDirect
Journal of the Egyptian National Cancer Institute
journal homepage: www.sciencedirect .comFull Length ArticlePatterns of care and survival among small cell lung cancer patients:
Experience from a tertiary center in Indiahttp://dx.doi.org/10.1016/j.jnci.2016.10.001
1110-0362/ 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of The National Cancer Institute, Cairo University.
⇑ Corresponding author at: Department of Radiation Oncology, PGIMER, India.
E-mail address: renumadan10@yahoo.com (R. Madan).
Please cite this article in press as: Julka PK et al. Patterns of care and survival among small cell lung cancer patients: Experience from a tertiary ce
India. J Egyptian Nat Cancer Inst (2016), http://dx.doi.org/10.1016/j.jnci.2016.10.001Pramod K. Julka, Daya Nand Sharma, Renu Madan ⇑, Supriya Mallick, Rony Benson, Haresh Kunhi P,
Subhash Gupta, Goura K. Rath
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
a r t i c l e i n f o a b s t r a c tArticle history:
Received 8 April 2016
Received in revised form 7 October 2016
Accepted 8 October 2016
Available online xxxx
Keywords:
Small cell lung cancer
Patterns of care
Chemotherapy
Radiotherapy
OutcomeBackground/purpose: Lung cancer is the commonest malignancy and the most common cause of cancer
related mortality in males worldwide. Non-small cell lung cancer (NSCLC) is the commonest histology
while small cell lung cancer (SCLC) contributes to only 15% of all cases of lung cancer. This report
intended to present the patterns of care, survival outcomes and prognostic factors of SCLC treated in a
tertiary care institute.
Results: A total of 85 patients of SCLC were registered in radiotherapy unit I during the period January,
2005 to December, 2012. The median age of the cohort was 56.5 years (95% CI 34–72). The majority of
the patients were male with a male:female ratio of 6.7:1. Sixty eight percent of the patients were smok-
ers. Sixty percent patients presented with extensive stage disease. Radiotherapy (RT) was used in 76% of
the patients while chemotherapy was used in 75% of the patients. Platinum Etoposide was the most com-
mon regimen which was used in 70% of the patients who received chemotherapy. The median progres-
sion free survival (PFS) of the entire cohort was 11.4 months (95% CI 9.11–13.58 months). Stage,
performance status, and use of chemotherapy were found to be significant factors affecting survival out-
come in patients with SCLC.
Conclusion: The pattern of care and survival outcomes in the present study parallels that of the various
published retrospective reviews. Basic research and development of targeted agents may be the way for-
ward in improving the outcome of patients with SCLC.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Worldwide lung cancer is the most common malignancy and
the commonest cause of mortality among male. Also, in India car-
cinoma lung has been reported to be the commonest malignancy
from all Population Based Cancer Registries (PBCR). Eighty five per-
cent of lung carcinoma has been classified as non-small cell lung
cancer (NSCL) and remaining 15% as small cell lung carcinoma
(SCLC) [1]. The prognosis in SCLC has remained dismal with a sur-
vival of about 24 months for limited stage and 12 months for
extensive stage. It is well known that small cell lung cancer is a
systemic disease and systemic chemotherapy is the back bone of
the treatment [2]. After the introduction of Cisplatin and Etoposide
chemotherapy and early integration of radiotherapy (local and pro-phylactic cranial), further steps to improve outcomes have not
been successful [3,4]. Better knowledge of molecular pathology
of these tumors may help in developing newer agents that may
improve survival [5]. This retrospective review is intended to pre-
sent the demographic features, patterns of care, survival outcome
and pattern of recurrence in SCLC patients treated at a tertiary care
center in north India.Patients and methods
Medical records of lung cancer patients treated from 2005 to
2012 were retrieved. Patient and treatment related variables doc-
umented in the file were recorded on a structured proforma. These
factors were age, sex, symptoms, symptom duration, Eastern coop-
erative oncology group (ECOG) performance status (PS), smoking,
medical co-morbidities and stage, treatment intent, type and num-
ber of chemotherapy cycles, radiotherapy (RT) dose fractionation
and toxicity to treatment.nter in
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All patients were evaluated with contrast enhanced computed
tomography scan of the chest and abdomen, bone scan, contrast
enhanced magnetic resonance imaging (MRI), serum LDH, com-
plete blood count, liver and kidney function test and pulmonary
function test. A positron emission tomography (PET) scan was
advised only in selected cases with high disease burden for suspi-
cion of metastasis. Patients were categorized in limited and exten-
sive stage following Veterans Administration Lung Study Group
(VALG). Treatment was done by multidisciplinary approach follow-
ing departmental protocol. Patients with limited stage disease
were treated with chemotherapy with Cisplatin and Etoposide
for 1–2 cycles and then subjected to concurrent radiation with
chemotherapy. Radiation was planned by conformal technique to
a dose of 45 Gy in 25 fractions in 5 weeks followed by boost of
10 Gy in 5 fractions over 1 week. After completion of thoracic radi-
ation the responders were treated with prophylactic cranial radia-
tion 25 Gy in 10 fractions over 2 weeks. For the thoracic radiation
the target volume included the post chemotherapy primary tumor
with 1 cm isotropic expansion (pCTV) and pre chemotherapy nodal
volume with 1 cm isotropic expansion (nCTV). The final planning
target volume (PTV) was delineated by adding 1 cm isotropic
expansion to the clinical target volume. Patients with extensive
stage disease were treated with palliative chemotherapy with a
platinum and Etoposide containing regimen for 4–6 cycles and
prophylactic cranial radiation in responders. Thoracic radiation
was used for patients with complete or near complete
response in extra-thoracic metastasis. A dose of 30 Gy in 10
fractions over 2 weeks was used for consolidation in responders.
Target volume was considered similar to patients with limited
stage disease.Table 1Follow up
After completion of treatment patients were followed up every
three months in curative patients and every month for metastatic
patients. The follow up included detailed physical examination and
a chest X-ray. A PET-CT or CECT thorax and abdomen was advised
every three to six months. PFT was done every six months or as
indicated for post radiotherapy cases.Summary of patient characteristics.
Patient characteristics SCLC
n %
Age <39 5 5.9
40–49 11 12.9
50–59 38 44.7
60–69 25 29.4
>70 6 7.1
Gender Male 74 87.1Toxicity evaluation and response
Weekly complete blood counts were done during chemo-
radiotherapy and were repeated 3–5 days before each cycle of
adjuvant chemotherapy. Patients were evaluated for toxicities
using common terminology criteria for adverse events
version 2.0.Female 11 12.9
Presenting symptom Cough 54 63.5
Chest pain 32 37.7
Breathlessness 35 41.2
Hemoptysis 23 27.1
Performance status 0–1 34 40
2–3 44 51.8
4 7 8.2
Smoking Yes 58 68.2
No 27 31.8
Median pack years 30
Co-morbidity Yes 20 23.5
No 65 76.5
Stage LS 34 40
ES 51 60Statistical analysis
All categorical variables were summarized by frequency (%) and
quantitative variables were summarized by median and range.
SPSS version 16.0 was used for all statistical analysis. Survival
outcomes were calculated from the date of diagnosis. Progression
free survival (PFS) was calculated from the date of diagnosis to
the date of progression. Overall survival was calculated
from the date of diagnosis to the date of death from any cause.
Kaplan–Meier method was used for survival analysis. Univariate
analysis (log rank test) was used to assess the impact of
prognostic variables on survival. A p value of <0.05 was taken as
significant.Please cite this article in press as: Julka PK et al. Patterns of care and survival a
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Patient characteristics
Data were retrieved for 593 cases of carcinoma lung registered
from 2005 to 2012. Out of these, 85 patients were diagnosed to
have small cell carcinoma lung, thus accounting for 14.4% of all
lung cancer cases. The patient characteristics have been described
in Table 1. Median age of the cohort was 56.5 years (95% CI 34–72).
Sixteen patients (18.6%) were younger than 50 years. Five patients
were younger than 40 years. Fifty eight patients (68%) were current
smokers. Remaining patients were found nonsmokers. Majority of
the patients in this cohort were male with a male:female ratio of
6.7:1. Patients were categorized in limited and extensive stage fol-
lowing Veterans Administration Lung Study Group (VALG). Thirty
four patients (40%) had limited stage while 51 (60%) had extensive
stage. In patients with extensive stage at presentation, liver was
the most common site of metastasis seen in 21 (41.2%) of the
patients followed by bone 14 (27.4%) and brain 12 (23.5%). Pleural
effusion was found in 9 (17.6%) and non-regional lymph nodes in
10 (19.6%) of the patients. Spleen and skin metastases were found
in 2% of the patients.Treatment details
The treatment intent was curative in 27 patients (30%) while
palliative in 44 patients (52%). The treatment characteristics have
been summarized in Table 2. Patients with limited stage disease
were treated with chemotherapy with Cisplatin and Etoposide
for 1–2 cycles and then subjected to concurrent radiation with
chemotherapy. Patients with extensive stage disease were treated
with palliative chemotherapy with a Platinum and Etoposide con-
taining regimen for 4–6 cycles and thoracic and prophylactic cra-
nial radiation in responders. Thoracic radiation was used for
patients with complete or near complete response in extra-
thoracic metastasis. Radiotherapy was used in 65 patients (76%)
while chemotherapy was used in 64 patients (75%). Platinum-
Etoposide was the commonest regimen which was used on 45
patients (70% of the patients receiving chemotherapy in the firstmong small cell lung cancer patients: Experience from a tertiary center in
0.001
Fig. 2. Progression free survival with use of chemotherapy in patients with small
cell lung cancer.
Table 2
Summary of treatment details of the entire cohort.
Treatment characteristics n %
Treatment Intent n = 85 Radical 27 31.7
Palliative 44 51.8
Best supportive care 14 16.5
Radiotherapy 65 76.4
Chemotherapy 64 75.3
Radiotherapy n = 65 Radical thoracic 26 40
Palliative 39 60
Chemotherapy n = 64 Radical 27 42.2
Palliative 37 57.8
CT Regimen n = 64 Platin Etoposide 45 70.3
Platin Irinotecan 14 21.9
Other 5 7.8
Response first line treatment n = 71 Complete response 18 25.3
Partial response 22 31.1
Stable disease 10 14.1
Progression 15 21.1
Unknown 6 8.4
P.K. Julka et al. / Journal of the Egyptian National Cancer Institute xxx (2016) xxx–xxx 3line). Doublet chemotherapy of platinum (Cisplatin or Carboplatin)
and Etoposide was given as first line chemotherapy in all patients
with a good general condition. Cisplatin was given at 80 mg/m2
and Carboplatin at an area under curve of 5 (AUC-5) on day 1 while
Etoposide was given at a dose of 100 mg/m2 for 3 days. The
chemotherapy cycles were repeated every three weeks. The
chemotherapy was given for 4 to 6 cycles in early stage disease
while 6–8 cycles were given in extensive stage SCLC.Fig. 3. Progression free survival with Karnofsky performance status in patients with
small cell lung cancer.Treatment outcomes
Complete and partial response to primary treatment was seen
in 25% and 31% patients respectively. Median PFS of the entire
cohort was 11.4 months (95% CI 9.11–13.58 months) (Fig. 1).
Patients with limited stage disease had significantly better PFS
compared to extensive stage [20.3 (95% CI 12.334–28.265) vs.
10.9 (95% CI 7.746–14.221), p < 0.001]. On univariate analysis,
ECOG PS (2 or less vs. 3 or more) was a significant factor associated
with better PFS [13.7 (95% CI 10.406–17.135) vs. 6.6 (95% CI
4.700–8.546) months, p = <0.001]. Similarly the use of chemother-
apy versus no chemotherapy was also found to be a significant
factor affecting PFS [13.4 (95% CI 10.040–16.058) vs. 4.8 (95% CI
0.832–8.938) months, p – <0.001]. However, age (660 vs. >60),
sex, smoking, or the presence of co-morbidities were not foundFig. 1. Progression free survival in patients with small cell lung cancer.
Fig. 4. Progression free survival with stage of disease in patients with small cell
lung cancer.
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in Figs. 2–4. In multivariate analysis stage of disease and use of
chemotherapy remained to be significant for PFS. The impact of
prognostic variables has been tabulated in Table 3.mong small cell lung cancer patients: Experience from a tertiary center in
0.001
Table 3
Summary of impact of different variables in treatment outcome (univariate and multivariate analysis).
Factor Number of
patients
Number of
events
Univariate analysis Multivariate analysis
Median PFS 95% confidence interval p Value Hazard
Ratio
95% Confidence
interval
p Value
PS 62 62 38 13.7(10.406–17.135) vs. 6.6(4.700–8.546) p = <0.001 1.966 0.0768–5.034 0.159
P3 23 10
Chemotherapy use Yes 64 39 13.4 (10.040–16.058) vs. 4.8(0.832–8.938) p = <0.001 1.645 1.255–2.155 <0.001
No 21 9
Stage Limited 51 28 20.3(12.334–28.265) vs. 10.9(7.746–14.221) p = <0.001 2.857 1.447–5.641 0.002
Extensive 34 20
Age 660 64 36 11.41 (9.22–13.59) vs. 9.219 (6.46–11.96) p  0.886 – – –
P61 21 12
Sex Male 74 42 11.34(10.31–12.37) vs. 14.62 (5.38–22,386) p  0.915 – – –
Female 11 6
Co-morbidities Yes 20 36 11.11(9.03–13.20) vs. 14.82 (9.11–13.57) p  0.195
No 65 12
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Eighteen patients (21%) had progression to the first line treat-
ment. Systemic failure was the most common pattern of failure,
seen in 78.8% patients. Loco-regional progression was seen in
21.3% patients. 36.7% experienced local failure along with systemic
failure. On progression 72.7% patients received second line
chemotherapy. RT was offered only in 6% of the patients. 24.2%
of the patients were not found suitable for any further cancer
directed therapy and were kept on best supportive care. Same
chemotherapy was used in patients recurring after 6 months of
chemotherapy, while Irinotecan was used as second line
chemotherapy in patients progressing before 6 months. Docetaxel,
Gemcitabine, Vinorelbine were used in third line in patients with
good performance status.Discussion
SCLC is a neuroendocrine carcinoma characterized by aggres-
sive behavior, and frequent association with distinct para-
neoplastic syndromes including hypercalcemia, Eaton-lambert
syndrome, syndrome of inappropriate diuretic hormone and many
others [6]. SCLC also exhibits sensitivity to chemotherapy and radi-
ation [7]. Retrospective studies and audits help in giving a real
world scenario of the particular problem outside a clinical trial
and are helpful for evaluation of health service and to focus on
many unaddressed issues. This is retrospective evaluation of SCLC
patients treated over a period of 7 years.
In the present analysis SCLC contributed to 14.4% cases of the
total lung cancer cases corroborating with figure from published
literature [8]. Sixty percent patients presented with extensive
stage disease. This is showing similarity with some of the western
literature reporting that about 2/3 of the patients with small cell
lung cancer present in an advanced stage [9,10].
In this series only 68% patients had a history of smoking which
is low when compared to other published literature which shows
more than 90% of the patients were smokers [11]. Though tobacco
consumption in India is high; the rural population prefers smoke-
less tobacco. In the present series, males outnumbered females
with a male to female ratio of 6.7:1. This finding is same as a pub-
lished literature that showed a male preponderance for SCLC
although the ratio is higher compared to western data [12]. This
may be due to a low incidence of smoking among Indian females.
When looked into the pattern of distant metastasis at presentation,
liver was the most common site of metastasis seen in 21 (41.2%) of
the patients followed by bone metastasis in 14 patients (27.4%) andPlease cite this article in press as: Julka PK et al. Patterns of care and survival a
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orating with other published literature [13]. The high rate of sys-
temic dissemination points toward necessity of extensive
evaluation as staging work up in SCLC which also reflects the ratio-
nale of PCI in both stages of SCLC. The addition of PCI has been
shown to improve survival in early stage and extensive stage SCLC
[14,15].
SCLC being a systemic disease is usually treated with a com-
bined modality approach of radio-chemotherapy. The addition of
thoracic radiation has been found to add survival benefit in these
patients [16]. In addition, it has been found that hyper-
fractionated radiotherapy and early institution of thoracic RT
may confer survival advantage in these patients [17]. It was
intended to start thoracic RT as early as possible, preferably with
the second cycle of chemotherapy. However, long waiting period
forces some patients to receive delayed RT. The logistic reason also
prevents us from implementing the hyper-fractionated regimen in
these patients.
Cisplatin plus Etoposide has remained the standard first line
therapy in SCLC. Although some Japanese studies have shown
Irinotecan based chemotherapy to be conferring some survival
benefit [18]. Similar studies from west have not shown the same
results [3]. In present series 70% of the patients received a Platinum
Etoposide doublet as first line therapy while 22% received Irinote-
can Platinum chemotherapy.
In present series the median PFS for the entire cohort was
11.4 months, which appears to be in agreement with that of other
reported series [19,20]. However, lack of information regarding
death stopped us from doing an overall survival analysis. This is
a common situation in developing countries where it is not possi-
ble to track the patients till end, with lack of adequate facilities and
illiteracy being major contributing factors.
When univariate analysis was done to find out the prognostic
factors stage, KPS and use of chemotherapy were found to be sig-
nificant prognostic factors for survival. This can be seen in parallel
to other published literature that shows KPS, stage and use of
chemotherapy to be significant prognostic factors [21,22]. The fact
that patients with poor performance status were not considered
for chemotherapy and succumbed to disease may have also con-
tributed to the results. In this study age, sex, smoking, or the pres-
ence of co-morbidities was not found to be significant prognostic
factors influencing PFS. This may be due to the less number of
patients. The management of NSCLC has been revolutionized in
the recent years with the better knowledge of the molecular path-
ways and thus development of targeted agents. The targeted
agents are of importance because they are an effective treatmentmong small cell lung cancer patients: Experience from a tertiary center in
0.001
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important for further improvement in outcomes in SCLC as major-
ity of the patients present in an advanced stage and is usually
elderly population. Since treatment intensification may not be a
valid option in fear of toxicity to the particular age group, develop-
ment of such targeted agents is a necessity and translational
research is necessary for this.
The present series has several limitations owing to the retro-
spective nature of the study. The lack of end status of patients after
recurrence is heartening. It is noteworthy that after recurrence
many patients are deemed non salvageable and the poverty in
developing countries precludes regular follow up. The effectiveness
of this combined modality approach in an unselected patient pop-
ulation outside a clinical trial simulating a real world scenario and
can be considered as strength of the data.
Conclusion
The pattern of care in the present study parallels that of the var-
ious published retrospective reviews. The progression free survival
in this cohort was comparable to other published literature. Stage,
performance status, and use of chemotherapy were found to be
significant factors affecting survival outcome in these patients.
Translational research and development of targeted agents may
be the way forward in improving outcome in these patients.
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